- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01836172
YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus
Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus
Study Overview
Detailed Description
The primary purpose of this study is to demonstrate superior effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of flow-mediated dilation (FMD), compared to placebo group after treatment of 12 weeks.
The secondary purposes of this study are divided into three as follows;
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on endothelial dysfunction in diabetes mellitus indicated as mean change difference of FMD, compared to placebo group after treatment of 8 weeks.
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on insulin resistance in diabetes mellitus indicated as mean change difference of Homeostasis Model Assessment-Insulin Resistance (HOMA-IR), compared to placebo group after treatment of 4, 8 and 12 weeks.
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on mean change difference of blood pressure in diabetes mellitus, compared to placebo group after treatment of 4, 8 and 12 weeks.
The exploratory purposes of this study are divided into two as follows;
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on blood glucose level in diabetes mellitus indicated as mean change difference of HbA1c, compared to placebo group after treatment of 12 weeks.
- Clinically significant effect of YJP-14 three doses, 25, 50 and 100 mg t.i.d on vascular stiffness in diabetes mellitus indicated as mean change difference of blood lipids (LDL, HDL and TG), compared to placebo group after treatment of 12 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Internal medicine, Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing treatment with an oral hypoglycemic agent), Endothelial dysfunction: FMD below 6.7%, LDL cholesterol level less than 140 mg/dl, Patients agreed to Informed Consent Form
Exclusion Criteria: (Key exclusion criteria) Uncontrolled arterial hypertension (above 139/90 mmHg) or hypotension (below 80/50 mmHg), Severe diabetic complication: diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic vascular complications
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo t.i.d.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Other Names:
|
Placebo Comparator: YJP-14 25 mg t.i.d.
YJP-14 25 mg t.i.d.
YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Other Names:
|
Placebo Comparator: YJP-14 50 mg t.i.d.
YJP-14 50 mg t.i.d.
YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Other Names:
|
Placebo Comparator: YJP-14 100 mg t.i.d.
YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
YJP-14 100 mg t.i.d.
|
An 50% ethanolic extract of Lindera obtusiloba stems
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Flow-mediated dilation (FMD)
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Flow-mediated dilation (FMD) Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) Systolic and Diastolic Blood Pressure
Time Frame: 8 weeks
|
8 weeks
|
Homeostasis model assessment-insulin resistance (HOMA-IR)
Time Frame: 4, 8, 12 weeks
|
4, 8, 12 weeks
|
Systolic and Diastolic Blood Pressure
Time Frame: 4, 8, 12 weeks
|
4, 8, 12 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HbA1c Serum lipids (LDL, HDL and TG)
Time Frame: 12 weeks
|
12 weeks
|
Serum Lipids (LDL, HDL and TG)
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Byung-Hee Oh, M.D., Ph.D., Seoul National University Hospital
Publications and helpful links
General Publications
- Lee JO, Oak MH, Jung SH, Park DH, Auger C, Kim KR, Lee SW, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems causes NO-mediated endothelium-dependent relaxations in rat aortic rings and prevents angiotensin II-induced hypertension and endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):635-45. doi: 10.1007/s00210-011-0643-9. Epub 2011 May 2.
- Lee JO, Auger C, Park DH, Kang M, Oak MH, Kim KR, Schini-Kerth VB. An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice. PLoS One. 2013 Jun 3;8(6):e65227. doi: 10.1371/journal.pone.0065227. Print 2013.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HW2012-YJP002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Complication
-
Chinese University of Hong KongCompleted
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
Assiut UniversityNot yet recruiting
-
Dow University of Health SciencesCompleted
-
Amalgam Rx, Inc.Kansas City Area Life Sciences Institute, Inc.; University of Kansas; LifeScanUnknown
-
Shanghai Zhongshan HospitalRecruitingCardiovascular Diseases | Diabetes Mellitus | Complication DiabeticChina
-
Aristotle University Of ThessalonikiUniversity of Sheffield; University Hospital TuebingenCompletedDiabetes Mellitus | Diabetic Foot | Diabetic Neuropathies | Diabetic ComplicationGreece
-
Eastern Virginia Medical SchoolUnknownSweat Gland Diseases | Autonomic Nervous System Diseases | Diabetic Neuropathy With Neurologic ComplicationUnited States
-
Asst Melegnano e MartesanaEnrolling by invitationMortality | Nephrotoxicity | Respiratory Complication | Neurological Complication | Surgical Complication | Metabolic Complication | Cardiovascular ComplicationItaly
-
University of ChileActive, not recruitingType 2 Diabetes Mellitus | Periodontitis | Diabetic Complication | Dental CareChile
Clinical Trials on YJP-14
-
PfizerCompleted
-
Robert Jones and Agnes Hunt Orthopaedic and District...Smith & Nephew, Inc.Recruiting
-
PATHCompletedEncephalitis, Japanese BPhilippines
-
Jiaxing AnDiCon Biotech Co.,LtdRecruiting
-
SRI InternationalRecruitingToxicity;ChemicalUnited States
-
Federal Budgetary Research Institution State Research...CompletedSmallpox | Monkeypox | Cowpox | Vaccinia Virus InfectionRussian Federation
-
PATHCompleted
-
Boehringer IngelheimCompleted
-
University of CopenhagenCompletedPolycystic Ovary Syndrome (PCOS)Denmark